PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
M He, C Cao, Z Ni, Y Liu, P Song, S Hao, Y He… - … and Targeted Therapy, 2022 - nature.com
Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
Intracellular delivery of glutathione peroxidase degrader induces ferroptosis in vivo
T Luo, Q Zheng, L Shao, T Ma, L Mao… - Angewandte …, 2022 - Wiley Online Library
Ferroptosis is a new form of regulated, non‐apoptotic cell death driven by iron‐dependent
phospholipid peroxidation. Its therapeutic potential is however, greatly limited by the low …
phospholipid peroxidation. Its therapeutic potential is however, greatly limited by the low …
Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy
J Pei, X Pan, A Wang, W Shuai, F Bu, P Tang… - Chemical …, 2021 - pubs.rsc.org
Autophagy-based protein degradation is emerging as a promising technology for anti-
diseases and innovative drug discovery. Here, we demonstrate a novel type of autophagy …
diseases and innovative drug discovery. Here, we demonstrate a novel type of autophagy …
[HTML][HTML] Recent advances in PROTACs for drug targeted protein research
Proteolysis-targeting chimera (PROTAC) is a heterobifunctional molecule. Typically,
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
PROTAC consists of two terminals which are the ligand of the protein of interest (POI) and …
Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione Derivative Inhibits d-Dopachrome Tautomerase Activity and Suppresses the Proliferation of Non-Small Cell Lung Cancer …
The homologous cytokines macrophage migration inhibitory factor (MIF) and d-dopachrome
tautomerase (d-DT or MIF2) play key roles in cancers. Molecules binding to the MIF …
tautomerase (d-DT or MIF2) play key roles in cancers. Molecules binding to the MIF …
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …
therapeutic resistance, which is partially driven by the undruggable proteome. The …
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Proteolysis-targeting chimeras (PROTACs) represent a transformative advancement in drug
discovery, offering a method to degrade specific intracellular proteins. Unlike traditional …
discovery, offering a method to degrade specific intracellular proteins. Unlike traditional …
Destabilization of macrophage migration inhibitory factor by 4‐IPP reduces NF‐κB/P‐TEFb complex‐mediated c‐Myb transcription to suppress osteosarcoma …
L Zheng, Z Feng, S Tao, J Gao, Y Lin… - Clinical and …, 2022 - Wiley Online Library
Background As an inflammatory factor and oncogenic driver protein, the pleiotropic cytokine
macrophage migration inhibitory factor (MIF) plays a crucial role in the osteosarcoma …
macrophage migration inhibitory factor (MIF) plays a crucial role in the osteosarcoma …
Dual‐Programmable Semiconducting Polymer NanoPROTACs for Deep‐Tissue Sonodynamic‐Ferroptosis Activatable Immunotherapy
Proteolysis‐targeting chimeras (PROTACs) can provide promising opportunities for cancer
treatment, while precise regulation of their activities remains challenging to achieve effective …
treatment, while precise regulation of their activities remains challenging to achieve effective …